EVT801: Standalone cancer immunotherapy in VEGFR3+ tumors and combination with immune checkpoint therapies in VEGFR3- tumors

被引：1
|
作者：
Esquerre, Michael
Fons, Pierre
Badet, Gaelle
Barron, Pauline
Kagan, Jeremy
Alam, Antoine
Meneyrol, Jerome
Blanc, Isabelle
Broussy, Roselyne
Gaujarengues, Florence
Lisztwan, Joanna
Paillasse, Michael
Whittaker, Mark
Bono, Francoise
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-2634
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2634
引用
收藏
页数：2
相关论文
共 13 条
  • [1] Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy
    Paillasse, Michael R.
    Esquerre, Michael
    Bertrand, Florie A.
    Poussereau-Pomie, Celine
    Pichery, Melanie
    Visentin, Virgile
    Gueguen-Dorbes, Genevieve
    Gaujarengues, Florence
    Barron, Pauline
    Badet, Gaelle
    Briaux, Anne
    Ancey, Pierre-Benoit
    Sibrac, David
    Erdociain, Eric
    Oezcelik, Dennis
    Meneyrol, Jerome
    Martin, Valerie
    Gomez-Brouchet, Anne
    Selves, Janik
    Rochaix, Philippe
    Battistella, Maxime
    Lebbe, Celeste
    Delord, Jean-Pierre
    Dol-Gleizes, Frederique
    Bono, Francoise
    Blanc, Isabelle
    Alam, Antoine
    Hunneyball, Ian
    Whittaker, Mark
    Fons, Pierre
    CANCER RESEARCH COMMUNICATIONS, 2022, 2 (11): : 1504 - 1519
  • [2] EVT801: a selective VEGFR3 inhibitor with the potential for combination with immune-checkpoint therapies, preclinical evidences and plans for first-in-human evaluation
    Fons, Pierre
    Esquerre, Michael
    Paillasse, Michael
    Visentin, Virgile
    Dol, Frederique
    Meneyrol, Jerome
    Badet, Gaelle
    Cogo, Eric
    Vidaud, Lionel
    Alam, Antoine
    Blanc, Isabelle
    Bono, Francoise
    Lisztwan, Joanna
    Poublanc, Muriel
    Filleron, Thomas
    Hunneyball, Ian
    Delord, Jean-Pierre
    Whittaker, Mark
    CANCER RESEARCH, 2019, 79 (13)
  • [3] VEGFR-3 expression profiling by histology to classify patient population for the selective VEGFR-3 inhbitor EVT801
    Paillasse, Michael
    Ancey, Pierre-Benoit
    Badet, Gaelle
    Gomez-Brouchet, Anne
    Selves, Janik
    Rochaix, Philippe
    Battistella, Maxime
    Lebbe, Celeste
    Cassier, Philippe
    Gomez-Roca, Carlos
    Delord, Jean-Pierre
    Whittaker, Mark
    Davenne, Lise
    Friend, John
    Fitzgerald, Michael
    Garner, James
    Fons, Pierre
    CANCER RESEARCH, 2023, 83 (07)
  • [4] VEGFR-3 expression profiling by histology and mRNA signature to classify patient population for the selective VEGFR-3 inhibitor EVT801
    Gomez-Roca, C. A.
    Fons, P.
    Ancey, P. B.
    Cassier, P.
    Delord, J. P.
    Davenne, L.
    Fitzgerald, M.
    Mandron, M.
    Paillasse, M. R.
    Friend, J.
    Rochaix, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S235 - S236
  • [5] EVT801, a novel selective VEGFR-3 inhibitor targeting tumor angiogenesis, is pursuing dose escalation stage of phase I first-in-human study
    Gomez-Roca, Carlos
    Cassier, Philippe
    Fitzgerald, Michael
    Davenne, Lise
    Costantin, Cristina
    Rochaix, Philippe
    Delord, Jean-Pierre
    Friend, John
    Nizzardo, Andrea
    Tagliavini, Alessia
    Pergher, Marco
    Fons, Pierre
    Mandron, Marie
    CANCER RESEARCH, 2024, 84 (07)
  • [6] EVT801, a novel selective VEGFR-3 inhibitor targeting tumor angiogenesis, started enrollment for its phase I first-in-human study.
    Roca, Carlos Gomez
    Cassier, Philippe
    Mandron, Marie
    Estrabaut, Myriam
    Delesque-Touchard, Nathalie
    Smith, Adam C.
    Klawitter, Amy
    Gentry, Leesa
    Fons, Pierre
    Paillasse, Michael R.
    Davenne, Lise
    Fitzgerald, Michael
    Garner, James
    Delord, Jean-Pierre
    CANCER RESEARCH, 2022, 82 (12)
  • [7] Analysis of immune infiltrate identifies checkpoint blockade and TLR3 activation as efficient synergistic combination of immunotherapy in rhabdoid tumors
    Leruste, Amaury
    Han, Zhi-Yan
    Tauziede-Espariat, Arnault
    Caudana, Pamela
    Waterfall, Joshua J.
    Andrianteranagna, Mamy
    Sedlik, Christine
    Ramos, Rodrigo
    Viel, Sophie
    Chauvin, Celine
    Delattre, Olivier
    Piaggio, Eliane
    Bourdeaut, Franck
    CANCER RESEARCH, 2018, 78 (19)
  • [8] The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies
    Yu, Puguang
    Zhu, Chunming
    You, Xiangyun
    Gu, Wen
    Wang, Xia
    Wang, Yuan
    Bu, Renge
    Wang, Kefeng
    CELL DEATH & DISEASE, 2024, 15 (06):
  • [9] AVID200, a first-in-class selective TGF-beta 1 and -beta 3 inhibitor, sensitizes tumors to immune checkpoint blockade therapies
    Tremblay, Gilles
    Gruosso, Tina
    Denis, Jean-Francois
    Figueredo, Rene
    Koropatnick, Jim
    O'Connor-McCourt, Maureen
    CANCER RESEARCH, 2020, 80 (16)
  • [10] Synergistic cancer immunotherapy combination of MVA-CD40L with tumor targeting antibodies or checkpoint blockade to achieve strong antitumor immune responses against large, established tumors
    Medina-Echeverz, Jose
    Hinterberger, Maria
    Giessel, Raphael
    Bathke, Barbara
    Kassub, Ronny
    Fiore, Giovanna
    Chaplin, Paul
    Hochrein, Hubertus
    Lauterbach, Henning
    CANCER RESEARCH, 2019, 79 (13)
12